Haematology research is embodied by a vibrant collaborative team of clinicians, scientists and allied health professionals employed within Monash Health, Monash University and the Hudson Institute of Medical Research. Together our research groups span the full spectrum of research from pre-clinical discovery through to early phase translation and late phase clinical trials and registry initiatives. Enabled by state-of-art facilities and clinical trial infrastructure within the Monash Health Precinct, our research program seeks to discover new treatments and provide cutting-edge therapeutics to our patients.
Our mission is to be at the forefront of scientific discovery, clinical translation, and best practice for patients with blood conditions to provide the best clinical outcomes.
Haematology research includes the study and treatment of ‘blood cancers’ (such as leukaemia, lymphoma and myeloma) and non-cancerous disorders of the blood and bone marrow (including bleeding and thrombotic disorders and bone marrow failure syndromes). Our research also seeks to define the best practice in supporting patients with blood disorders, with a particular focus on blood transfusion practices.
Head of Haematology Research, Department of Medicine
Prof Jake Shortt is the clinical lead at Monash Haematology for myeloid leukaemia, myelodysplasia and T-cell lymphoma. He is Principal Investigator on a range of clinical trials for T-cell lymphoma and myeloid malignancies, conducted through the Monash Haematology clinical trials unit.
Find out more about Prof Jake Shortt